Federal: S3677

Bill Summary

The Dietary Supplement Listing Act of 2026 (S3677) requires manufacturers and distributors of dietary supplements sold in the United States to register their products with the FDA and submit detailed ingredient information, including amounts per serving, directions, warnings, and health claims. The bill mandates creation of a publicly accessible electronic database of this information within two years of enactment and assigns compliance deadlines for existing and new supplements. Products that fail to comply with listing requirements will be considered misbranded. The legislation applies to both domestic and foreign manufacturers of supplements marketed in the U.S.

Why It Matters to MAHA

MAHA strongly supports this bill because it advances health freedom and patient autonomy through increased transparency without restricting access to dietary supplements. The requirement for detailed ingredient disclosure and a searchable FDA database empowers consumers to make fully informed choices about the supplements they purchase, addressing a core MAHA priority around healthcare transparency. The bill does not ban, restrict, or phase out any supplements, does not limit patient choice, and does not create unnecessary regulatory barriers to market entry. By ensuring manufacturers provide accurate, standardized information about their products, the legislation protects consumers from deceptive claims and undisclosed ingredients while maintaining robust access to the supplement marketplace.